Literature DB >> 22201713

Alpha-particle microdosimetry.

Nicolas Chouin1, Manuel Bardies.   

Abstract

With the increasing availability of alpha emitters, targeted α-particle therapy has emerged as a solution of choice to treat haematological cancers and micrometastatic and minimal residual diseases. Alpha-particles are highly cytotoxic because of their high linear energy transfer (LET) and have a short range of a few cell diameters in tissue, assuring good treatment specificity. These radiologic features make conventional dosimetry less relevant for that context. Stochastic variations in the energy deposited in cell nuclei are important because of the microscopic target size, low number of α- particle traversals, and variation in LET along the α-particle track. Microdosimetry provides a conceptual framework that aims at a systematic analysis of the stochastic distribution of energy deposits in irradiated matter. The different quantities of microdosimetry and the different methods of microdosimetric calculations were described in the early eighties. Since then, numerous models have been published through the years and applied to analyse experimental data or to model realistic therapeutic situations. Major results have been an accurate description of the high toxicity of α-particles, and the description of the predominant effect of activity distribution at the cellular scale on toxicity or efficacy of potential targeted α-particle therapies. This last factor represents a major limitation to the use of microdosimetry in vivo because determination of the source - target distribution is complicated. The future contributions of microdosimetry in targeted α-particle therapy research will certainly depend on the ability to develop high-resolution detectors and on the implementation of pharmaco-kinetic models at the tumour microenvironment scale.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22201713     DOI: 10.2174/1874471011104030266

Source DB:  PubMed          Journal:  Curr Radiopharm        ISSN: 1874-4710


  7 in total

1.  Application of 212Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation.

Authors:  Kwon Yong; Martin Brechbiel
Journal:  AIMS Med Sci       Date:  2015-08-18

Review 2.  Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2017-05-02       Impact factor: 3.959

Review 3.  Targeted α-particle therapy of bone metastases in prostate cancer.

Authors:  Hossein Jadvar; David I Quinn
Journal:  Clin Nucl Med       Date:  2013-12       Impact factor: 7.794

Review 4.  The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma.

Authors:  Evan D Read; Peter Eu; Peter J Little; Terrence J Piva
Journal:  Target Oncol       Date:  2014-05-29       Impact factor: 4.493

5.  Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.

Authors:  Massimiliano Pacilio; Guido Ventroni; Giuseppe De Vincentis; Bartolomeo Cassano; Rosanna Pellegrini; Elisabetta Di Castro; Viviana Frantellizzi; Giulia Anna Follacchio; Tatiana Garkavaya; Leda Lorenzon; Pasquale Ialongo; Roberto Pani; Lucio Mango
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-13       Impact factor: 9.236

Review 6.  The potential and hurdles of targeted alpha therapy - clinical trials and beyond.

Authors:  Jörgen Elgqvist; Sofia Frost; Jean-Pierre Pouget; Per Albertsson
Journal:  Front Oncol       Date:  2014-01-14       Impact factor: 6.244

7.  Targeting Prostate Cancer Stem Cells with Alpha-Particle Therapy.

Authors:  Jens Ceder; Jörgen Elgqvist
Journal:  Front Oncol       Date:  2017-01-09       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.